ST Wanbang: Announcement on Obtaining Ethics Approval for the Multi-dose Ramp-Up Clinical Study of Subsidiary WP107 Drug

Securities code: 002082 Securities abbreviation: ST Wanbang Announcement number: 2026-062

Wanbangde Pharmaceutical Holding Group Co., Ltd.

Announcement on Obtaining Ethics Approval for the Multi-dose Ramp-Up Clinical Study of Subsidiary WP107 Drug

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

The multi-dose ramping clinical trial study of WP107, a new drug independently developed by Vanband Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of Vanband Pharmaceutical Holding Group Co., Ltd. (hereinafter referred to as the "Company"), to treat systemic myasthenia gravis among healthy trial participants has received review approval from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital Affiliated to Wenzhou Medical University, approving the project. The relevant information is now announced as follows:

1. Basic information on obtaining ethics approval for drugs

Drug name: WP107 (Huperzine A Oral Solution)

English name: Huperzine A Oral Solution

Dosage form: oral solution

Specification: 0.22mg

Registration classification: US 505(b)1/China Class 2.2 new drug

Indications: Myasthenia gravis

Study content: Single-center, randomized, double-blind, multiple-dose, dose-escalating pharmacokinetic study Clinical study phase: Phase I

Clinical research unit: The Second Affiliated Hospital of Wenzhou Medical University

Ethics review committee review opinion: Agree to clinical trial

2. Basic information on drugs

Myasthenia gravis (MG) is a rare autoimmune disease caused by damage to synapses at the neuromuscular junction. The Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis (2025 Edition) show that the global prevalence is 12.4/100,000 people. The main clinical manifestations are partial or systemic skeletal muscle weakness and fatigue, which may include eyelid drooping, difficulty swallowing, weak speech, and even difficulty breathing.

Huperzine A is a highly selective acetylcholinesterase inhibitor, and its injection has shown significant improvement in MG symptoms in previous clinical trials. WP107, as an oral solution of huperzine A, is expected to provide MG patients around the world with clear efficacy, fewer adverse reactions, suitable for long-term use, and a more friendly clinical option for patients with dysphagia. It can play a good synergistic therapeutic effect with emerging biological agents such as FcRn blockers and complement inhibitors.

According to relevant research reports from Fortune Business Insights, the global myasthenia gravis treatment market size will be US$1.62 billion in 2025. The market is expected to grow from US$1.75 billion in 2026 to US$3.21 billion in 2034, at a CAGR of 7.89% during 2026-2034. North America will dominate the global market with a share of 49.25% in 2025.

3. Progress of drug clinical trials

The company received orphan drug designation for huperzine A for the treatment of myasthenia gravis from the U.S. FDA in 2023. In 2025, it obtained a new drug clinical trial license for WP107 oral solution from the U.S. FDA and a clinical trial approval notice for a new chemical drug Class 2.2 from the China National Medical Products Administration. It also completed a clinical comparative study on the pharmacokinetic characteristics of huperzine A oral solution and huperzine A injection according to the research and development plan. Subsequently, the product was approved by the FDA in July 2026 for use in multi-dose ramping clinical trials of healthy trial participants, and the company is advancing relevant clinical research work in an orderly manner.

This review and approval was received from the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University/Yuying Children's Hospital of Wenzhou Medical University. The purpose is to evaluate the pharmacokinetic characteristics, safety and tolerability of Huperzine A oral solution after multiple administrations in healthy trial participants.

4. Risk warning

After this clinical trial obtains the ethics review approval from the clinical unit, it will not have a significant impact on the company's operating performance in the short term. The company will continue to conduct clinical trials in accordance with relevant regulations and requirements. Drug research and development is characterized by high investment, high risk, and long cycle. There are uncertainties in the progress and results of clinical trials and the future product market competition situation.

The company will actively promote the above-mentioned research and development projects and perform its information disclosure obligations on the subsequent progress of the projects in a timely manner in strict accordance with relevant regulations. Investors are kindly requested to pay attention to guard against investment risks.

Announcement is hereby made.

Board of Directors of Wanbangde Pharmaceutical Holding Group Co., Ltd.

August 19, 2026